



OPEN HEALTH

# ISPOR EU 2024

NOVEMBER 17-20, 2024 | BARCELONA, SPAIN | BOOTH 913

## Short Course

TITLE	OPEN HEALTH PRESENTERS	SESSION
Going Beyond the Standard: Exploring Advanced Survival Modeling Techniques	Elisabeth Fenwick Claire Simons	Nov 17, 2024 1:00 - 5:00 PM (CET)

## Breakout Sessions

TITLE	OPEN HEALTH PRESENTER	SESSION
Should We Account for Variation in Patient Preferences in Health Technology Assessment? Individual Preferences With Respect to the Characteristics and Possible Outcomes of a Healthcare Intervention May Vary	Ben van Hout	Nov 18, 2024 10:15 - 11:15 AM (CET)
How Can We Move From Generating Robust Patient Preference Information to Producing Decision-Ready Outputs	Divya Mohan	Nov 19, 2024 13:45 - 14:45 PM (CET)
Ending the Struggle: How Can We Put Outcome-Based Risk Sharing Agreements Out of Their Misery	Elisabeth Fenwick	Nov 20, 2024 8:00 AM - 9:00 AM (CET)

## Poster Presentations

TITLE	OPEN HEALTH AUTHORS	SESSION
Cost-Effectiveness of Mavacamten for the Treatment of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) in France	Melissa Ho	Nov 18, 2024 Session 1
The Healthcare Resource Use Impact in Adults With Type 1 Diabetes Who Switched From a First to Another First or Next-Generation Basal Insulin Analogue: A Retrospective Linked Primary and Secondary Care Database Study in England	Xiacong Li Marston, Nick Delnholm	Nov 18, 2024 Session 1
Routes to Diagnosis for Lung Cancer in England: Examining the Patient Journey Using Linked Data From Hospital Episode Statistics and the Diagnostic Imaging Database	Xiacong Li Marston	Nov 18, 2024 Session 1
Predicting Acceptability of Quantitative Evidence Synthesis for Joint Clinical Assessment Submissions: A Rating Scale	Dorothea Heldt, Divyesh Mistry, Claire Ainsworth, Sonja Kroep	Nov 18, 2024 Session 1
Utilizing Generative Artificial Intelligence in Network Meta-Analysis: Assessing the Effectiveness of GenAI as a Tool in Feasibility Assessments	Paige Pierce, Carla Kraan, Craig Bennison, Svenja Petersohn, Sonja Kroep	Nov 18, 2024 Session 1

[www.openhealthgroup.com](http://www.openhealthgroup.com)

© Copyright 2024 OPEN Health Company | All Rights Reserved

## Poster Presentations

TITLE	OPEN HEALTH AUTHORS	SESSION
From Data to Decisions: Decision-Makers' Perceptions of Artificial Intelligence-Powered Evidence Synthesis in HTA Submissions	Grace Fox, Emanuele Arca, Nita Santpurkar, Oliver Walker, Juliette Torres Ames	Nov 18, 2024 Session 1
A Budget Impact Model Assessing Continuous Blood Glucose Monitoring Devices in Type 2 Diabetes Mellitus in Sweden	Jessica Shi, Elizabeth Westerberg, Tim Ignacio, Sonja Kroep	Nov 18, 2024 Session 2
RSV-Passive Immunization Reduces Antimicrobial Consumption During RSV Infection in Infants and Young Children -5 Years in Japan	Viktor Chirikov	Nov 18, 2024 Session 2
Prevalence of Metabolic and Micro-Vascular Complications Among English Adult Patients With Type 1 Diabetes Who Were Initiated on Basal Insulin Analogues Between 2014 and 2019: A Population-Based Retrospective Cohort Study	Xiacong Li Marston; Nick Delnholm	Nov 18, 2024 Session 2
Patient Consensus on PICO Scoping for the Health Technology Assessment (HTA) Regulation: A Case for Delphi Methodology	Emanuele Arca, Adele Barlassina, Adaeze Eza	Nov 18, 2024 Session 2
Health State Utility Values for Sleep Disturbance and Early Morning Off Symptoms in Advanced Parkinson's Disease: A Vignette-Based Approach Using the EQ-5D	Pablo Prieto Arija, Marco Boeri	Nov 18, 2024 Session 2
Population-Average Effect Estimates of Quizartinib and Midostaurin in Newly Diagnosed Patients With FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukaemia, Using Multi-Level Network Meta-Regression	Svenja Petersohn, Elizabeth Westerberg, Sonja Kroep	Nov 19, 2024 Session 3
Stakeholder Engagement in HTA: A Matter for Consensus?	Emanuele Arca, Adele Barlassina, Niall Harrison	Nov 19, 2024 Session 3
Optimizing HTA Outcomes in Cost-Effectiveness Markets: A Case Study of Axicabtagene Ciloleucel	Sarah Webb, Jed Avissar, Victoria Brennan	Nov 19, 2024 Session 3
Early Value Assessments (EVAs) for Medtech by NICE: What Can We Learn so Far?	Victoria Brennan, Abi Davies-McArthur	Nov 19, 2024 Session 3
Quantifying Health Related Quality of Life Benefits From Patients Treated With Mavacamten for Obstructive Hypertrophic Cardiomyopathy (HCM) in China Based on the EXPLORER-CN Trial	Zoe Cheah, Claire Simons	Nov 19, 2024 Session 3
Heterogeneity in Biomarker Data Collection, Recording, and Availability Across European Sources of Oncology RWD & Potential Impacts on Pan-EU HTA Assessment	Fatemeh Saberi Hosnijeh, HH Liu, Nick Denholm, Emily Wilkes, Bethany Levick	Nov 19, 2024 Session 3
Indirect Treatment Comparisons: Current Practice and the Added Value of Multi-Level Network Meta-Regression	Lytske Bakker, J Shi, Svenja Petersohn, Sonja Kroep	Nov 19, 2024 Session 3



## Poster Presentations

TITLE	OPEN HEALTH AUTHORS	SESSION
Overall Survival in Individuals Diagnosed With Progressive Multifocal Leukoencephalopathy	Elizabeth Westerberg, Claire Simons, Craig Bennison	Nov 19, 2024 Session 4
Early Cost-Effectiveness Analysis of AI-Enhanced Remote Monitoring Solutions for Timely Detection of Advanced Parkinson's Disease in Finland	Lytske Bakker	Nov 19, 2024 Session 4
Self-Sustainability in HTA: Is a Proportionate Approach Really Proportionate?	Sarah Webb, J Sulanowska, Laurie Marlow	Nov 19, 2024 Session 4
Challenges in NMA Methodology Based on Re-Randomization vs Treat-through Trial Designs	Svenja Petersohn, Melissa Ho, Claire Ainsworth	Nov 19, 2024 Session 4
Feasibility of Target Trial Emulation (TTE) Study Design Using the Hospital Episode Statistics (HES) Database in England	Emily Wilkes, Luca Le Treust, Chris Rolfe, Stephen Boulton, Bethany Levick	Nov 19, 2024 Session 4
Are the Machines Ready to Take Over? Can Artificial Intelligence Replace a Human Reviewer for Literature Screening and Selection for Systematic Literature Reviews?	Petra Nass, Dominika Rekowska, Emanuele Arca, Nick Halfpenny	Nov 19, 2024 Session 4
Assessing the Impact of Introducing Mavacamten for the Treatment of Obstructive HCM on the Modelled System and Societal Level Burden in China	Zoe Cheah, Melissa Ho	Nov 20, 2024 Session 5
Value Drivers for Therapies in Fabry Disease: Findings From a European Payer and Clinician Study	Oliver Walker, Sonika Awasthy	Nov 20, 2024 Session 5
Who Will be Shaping European Health Technology Assessment? A Scoring System to Anticipate Individual Countries' Influence on, and Uptake of, Joint Clinical Assessments (JCA) in the European Union (EU)	Kristina Hartl, Tessa Gerrits, Emanuele Arca, Dominika Rekowska	Nov 20, 2024 Session 5
Comparative Efficacy of Treatments in Advanced/Metastatic Pancreatic Cancer: Demonstrating the Power of Multi-Level Network Meta Regression	Matt Knowles, Sonja Kroep	Nov 20, 2024 Session 5
Incorporating Social Determinants of Health (SDOH) Into a Screening Tool Using Machine Learning to Predict Lung Cancer Diagnosis	Bianca Jackson	Nov 20, 2024 Session 5
Identifying and Appraising Real-World Evidence Data Sources for the Overweight and Obesity Population Across the EU4 and the United Kingdom	Hannah Matthews, Nick Denholm, Y Daniju, D Gregory, Fateme Saberi Hosnijeh	Nov 20, 2024 Session 5
Literature Review on the Use of Synthetic Data and AI Advances for Patient-Centered, Sustainable HEOR	Viktor Chirikov, Sonja Kroep	Nov 20, 2024 Session 5